Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the United States and Europe. The majority of patients with advanced AMD have the wet form of the disease, which is characterized by abnormal growth of leaky blood vessels under the retina, damaging the macula and potentially causing vision loss. The primary goal of wet AMD treatment is to stop or slow disease progression to prevent vision loss. Several current therapies target vascular endothelial growth factor (VEGF), an approach that has demonstrated the ability to maintain and even improve visual acuity in wet AMD patients. The most frequently used anti-VEGF agents in wet AMD, administered via intravitreal injections, are Lucentis, Eylea, and off-label compounded Avastin. However, even with these therapies, opportunity remains for new wet AMD agents that can address several unmet needs, such as the need for treatments with more-convenient delivery profiles.

This Unmet Need content provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals in the treatment of wet AMD and the current level of unmet need associated with the disease. We analyze commercial opportunities and how emerging therapies may capitalize on these opportunities.

Table of contents

  • Dry And Wet Age-Related Macular Degeneration - Unmet Need - Detailed, Expanded Analysis
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in Wet AMD
        • Importance of Efficacy Attributes to Prescribing Decisions in Wet AMD — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Wet AMD — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Wet AMD — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Wet AMD — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Wet AMD — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Wet AMD — Europe
      • Stated vs. Derived Importance of Treatment Drivers and Goals
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Wet AMD — United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Wet AMD — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for Wet AMD
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for Wet AMD — United States
        • Overall Performance of Key Therapies for Wet AMD — Europe
        • Relative Performance of Key Therapies for Wet AMD Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for Wet AMD Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for Wet AMD Across Select Safety and Tolerability Attributes — United States
        • Relative Performance of Key Therapies for Wet AMD Across Select Safety and Tolerability Attributes — Europe
        • Relative Performance of Key Therapies for Wet AMD Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for Wet AMD Across Select Convenience of Administration Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Ophthalmologists' Satisfaction with the Performance of Key Therapies for Wet AMD on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — United States
        • Surveyed Ophthalmologists' Satisfaction with the Performance of Key Therapies for Wet AMD on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — Europe
      • Physician Rating of Unmet Need in Wet AMD
        • Surveyed Ophthalmologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Wet AMD — United States
        • Surveyed Ophthalmologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Wet AMD — Europe
        • Surveyed Ophthalmologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Wet AMD — United States
        • Surveyed Ophthalmologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Wet AMD — Europe
        • Surveyed Ophthalmologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Wet AMD — United States
        • Surveyed Ophthalmologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Wet AMD — Europe
      • Unmet Need in Wet AMD and Related Indications
        • Surveyed Ophthalmologists' Ascribed Level of Unmet Need in Wet AMD and Related Indications — United States
        • Surveyed Ophthalmologists' Ascribed Level of Unmet Need in Wet AMD and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Wet AMD Market and Emerging Therapy Insights
        • Opportunity: A New Therapy Offering Improved Visual Acuity in Patients with Wet AMD
        • Opportunity: A New Therapy Offering Improved Visual Acuity in Patients with Treatment-Resistant Wet AMD
        • Opportunity: A New Therapy for Wet AMD with a More-Convenient Delivery Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Wet AMD Target Product Profile: Attribute Importance
        • Wet AMD Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Wet AMD Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Wet AMD Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Wet AMD Market Simulations: Target Product Profiles Included in Scenario 1
        • Wet AMD Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Wet AMD Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Wet AMD Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Emma McFadden, PhD; Audreza Das, P.G. Dip.

Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy. 

Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.

 

Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group

She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her B.E. degree in Biotechnology from Birla Institute of Technology, a deemed university and her P.G. Diploma in Cancer Immunology & Biotechnology from University of Nottingham.


Related Reports

Dry And Wet Age-Related Macular Degeneration - Landscape & Forecast - Disease Landscape & Forecast

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three

View Details

Age-Related Macular Degeneration | Disease Landscape and Forecast | G7 | 2020

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis, and Reg...

View Details

Dry And Wet Age-Related Macular Degeneration - Special Topics - Dry And Wet Age-Related Macular Degeneration | Special Topics | Beovu: Nine Months Postlaunch For Wet AMD | US | 2020

Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of...

View Details